vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and LANDMARK BANCORP INC (LARK). Click either name above to swap in a different company.
LANDMARK BANCORP INC is the larger business by last-quarter revenue ($18.8M vs $18.7M, roughly 1.0× CytomX Therapeutics, Inc.). LANDMARK BANCORP INC runs the higher net margin — 27.0% vs -0.8%, a 27.8% gap on every dollar of revenue. On growth, LANDMARK BANCORP INC posted the faster year-over-year revenue change (14.0% vs -25.7%). Over the past eight quarters, LANDMARK BANCORP INC's revenue compounded faster (13.1% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Landmark Bancorp Inc is a U.S.-based bank holding company operating Landmark National Bank, primarily serving communities across Kansas. It provides a full range of personal and commercial banking services including deposit accounts, residential mortgages, commercial loans, and wealth management solutions, catering to individual consumers, small businesses and local mid-sized enterprises.
CTMX vs LARK — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $18.8M |
| Net Profit | $-154.0K | $5.1M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | — |
| Net Margin | -0.8% | 27.0% |
| Revenue YoY | -25.7% | 14.0% |
| Net Profit YoY | 97.6% | 7.8% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $18.8M | ||
| Q4 25 | — | $18.7M | ||
| Q3 25 | — | $18.2M | ||
| Q2 25 | $18.7M | $17.3M | ||
| Q1 25 | $50.9M | $16.5M | ||
| Q4 24 | $38.1M | $15.8M | ||
| Q3 24 | $33.4M | $15.9M | ||
| Q2 24 | $25.1M | $14.7M |
| Q1 26 | — | $5.1M | ||
| Q4 25 | — | $4.7M | ||
| Q3 25 | — | $4.9M | ||
| Q2 25 | $-154.0K | $4.4M | ||
| Q1 25 | $23.5M | $4.7M | ||
| Q4 24 | $18.9M | $3.3M | ||
| Q3 24 | $5.7M | $3.9M | ||
| Q2 24 | $-6.5M | $3.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 31.7% | ||
| Q3 25 | — | 33.4% | ||
| Q2 25 | -6.9% | 30.9% | ||
| Q1 25 | 44.4% | 34.7% | ||
| Q4 24 | 46.4% | 15.2% | ||
| Q3 24 | 12.3% | 30.3% | ||
| Q2 24 | -33.7% | 24.5% |
| Q1 26 | — | 27.0% | ||
| Q4 25 | — | 32.1% | ||
| Q3 25 | — | 27.1% | ||
| Q2 25 | -0.8% | 25.4% | ||
| Q1 25 | 46.2% | 28.5% | ||
| Q4 24 | 49.6% | 26.5% | ||
| Q3 24 | 17.2% | 24.8% | ||
| Q2 24 | -26.0% | 20.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | $0.66 | ||
| Q3 25 | — | $0.85 | ||
| Q2 25 | — | $0.75 | ||
| Q1 25 | — | $0.81 | ||
| Q4 24 | — | $0.47 | ||
| Q3 24 | — | $0.68 | ||
| Q2 24 | — | $0.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $31.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | — |
| Total Assets | $175.1M | $1.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $31.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $160.6M | ||
| Q3 25 | — | $155.7M | ||
| Q2 25 | $119.9M | $148.4M | ||
| Q1 25 | $25.0M | $142.7M | ||
| Q4 24 | $-456.0K | $136.2M | ||
| Q3 24 | $-23.5M | $139.7M | ||
| Q2 24 | $-31.2M | $128.3M |
| Q1 26 | — | $1.6B | ||
| Q4 25 | — | $1.6B | ||
| Q3 25 | — | $1.6B | ||
| Q2 25 | $175.1M | $1.6B | ||
| Q1 25 | $98.5M | $1.6B | ||
| Q4 24 | $120.5M | $1.6B | ||
| Q3 24 | $139.0M | $1.6B | ||
| Q2 24 | $159.2M | $1.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | — |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $21.6M | ||
| Q3 25 | — | $10.3M | ||
| Q2 25 | $-15.8M | $439.0K | ||
| Q1 25 | $-21.0M | $8.0M | ||
| Q4 24 | $-19.9M | $14.2M | ||
| Q3 24 | $-20.7M | $8.1M | ||
| Q2 24 | $-19.5M | $4.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $21.0M | ||
| Q3 25 | — | $10.1M | ||
| Q2 25 | $-15.8M | $354.0K | ||
| Q1 25 | $-21.2M | $8.0M | ||
| Q4 24 | $-20.0M | $11.9M | ||
| Q3 24 | $-20.7M | $7.8M | ||
| Q2 24 | $-19.6M | $3.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | 112.5% | ||
| Q3 25 | — | 55.4% | ||
| Q2 25 | -84.6% | 2.0% | ||
| Q1 25 | -41.6% | 48.4% | ||
| Q4 24 | -52.5% | 75.6% | ||
| Q3 24 | -62.1% | 49.3% | ||
| Q2 24 | -78.2% | 25.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.2% | ||
| Q3 25 | — | 1.4% | ||
| Q2 25 | 0.1% | 0.5% | ||
| Q1 25 | 0.2% | 0.3% | ||
| Q4 24 | 0.2% | 14.7% | ||
| Q3 24 | 0.1% | 1.8% | ||
| Q2 24 | 0.4% | 4.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.56× | ||
| Q3 25 | — | 2.09× | ||
| Q2 25 | — | 0.10× | ||
| Q1 25 | -0.89× | 1.71× | ||
| Q4 24 | -1.05× | 4.34× | ||
| Q3 24 | -3.61× | 2.06× | ||
| Q2 24 | — | 1.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
LARK
Segment breakdown not available.
